Egalet Corporation (NASDAQ:EGLT) traded down 0% on Friday . The stock traded as low as $1.06 and last traded at $1.08. 1,138,666 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 2,543,067 shares. The stock had previously closed at $1.08.
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $7.00 price target on shares of Egalet and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Stifel Nicolaus cut shares of Egalet from a “buy” rating to a “hold” rating and set a $1.50 price target for the company. in a research report on Wednesday. Finally, Gabelli cut shares of Egalet from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $6.20.
The company has a current ratio of 2.73, a quick ratio of 2.68 and a debt-to-equity ratio of -3.43. The company has a market capitalization of $46.47, a PE ratio of -0.32 and a beta of 0.44.
A number of large investors have recently bought and sold shares of the stock. NJ State Employees Deferred Compensation Plan purchased a new stake in Egalet during the third quarter valued at approximately $435,000. Goldman Sachs Group Inc. lifted its position in Egalet by 515.7% during the second quarter. Goldman Sachs Group Inc. now owns 123,454 shares of the specialty pharmaceutical company’s stock valued at $293,000 after acquiring an additional 103,402 shares during the last quarter. HighTower Advisors LLC lifted its position in Egalet by 0.9% during the second quarter. HighTower Advisors LLC now owns 268,644 shares of the specialty pharmaceutical company’s stock valued at $636,000 after acquiring an additional 2,408 shares during the last quarter. GMT Capital Corp purchased a new stake in Egalet during the second quarter valued at approximately $1,281,000. Finally, Virtu KCG Holdings LLC lifted its position in Egalet by 87.0% during the second quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock valued at $189,000 after acquiring an additional 37,155 shares during the last quarter. 54.05% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Equities Focus and is the sole property of of Equities Focus. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.equitiesfocus.com/2018/01/07/egalet-eglt-stock-price-down-0.html.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.